Online drug research firm drugs.com today released its list of the top 100 selling drugs in the United States for the first quarter of 2012. The top five sellers include drugs from Bristol-Myers Squibb Co. (NYSE: BMY), AstraZeneca PLC (NYSE: AZN), Merck & Co. (NYSE: MRK) and Japan’s Otsuka Pharmaceutical Co. In addition, GlaxoSmithKline (NYSE: GSK), Eli Lilly & Co. (NYSE: LLY) and Abbott Laboratories (NYSE: ABT) were among the top 10 sellers.
The list:
- Plavix (BMY) — $1.62 billion in sales
- Nexium (AZN) — $1.40 billion
- Ability (Otsuka) — $1.34 billion
- Singulair (MRK) — $1.24 billion
- Seroquel (AZN) — $1.16 billion
- Advair Diskus (GSK) — $1.14 billion
- Crestor (AZN) — $1.12 billion
- Cymbalta (LLY) — $1.03 billion
- atorvastatin (generic) — $0.95 billion
- Humira (ABT) — $0.93 billion
The biggest gain compared to the fourth quarter of 2011 went to the atorvastatin generic, which saw sales rise by nearly $450,000. The generic has drawn sales from Lipitor, made by Pfizer Inc. (NYSE: PFE), which lost patent protection last year. Lipitor sales fell by more than $760,000 in the quarter to just over $840,000.
A generic version of Plavix — clopidogrel — recently hit the market, so the top of the rankings may be in for a change later this year.
Paul Ausick
Take Charge of Your Retirement In Just A Few Minutes (Sponsor)
Retirement planning doesn’t have to feel overwhelming. The key is finding expert guidance—and SmartAsset’s simple quiz makes it easier than ever for you to connect with a vetted financial advisor.
Here’s how it works:
- Answer a Few Simple Questions. Tell us a bit about your goals and preferences—it only takes a few minutes!
- Get Matched with Vetted Advisors Our smart tool matches you with up to three pre-screened, vetted advisors who serve your area and are held to a fiduciary standard to act in your best interests. Click here to begin
- Choose Your Fit Review their profiles, schedule an introductory call (or meet in person), and select the advisor who feel is right for you.
Why wait? Start building the retirement you’ve always dreamed of. Click here to get started today!
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.